Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients November 18, 2026
Natera Announces Clinical Collaboration with Incyte on Interventional Ph 2 Study in CRC November 18, 2026
Quality of Life and Pain Outcomes Data from Ph 3 PANOVA-3 Trial of Tumor Treating Fields for Pancreatic Cancer Published November 18, 2026
Lirafugratinib (Lyrfigtu) Added to NCCN Guidelines as 2L Therapy for Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement November 11, 2026
FDA PDUFA Date for Resubmitted NDA for Rivoceranib + Camrelizumab combo in 1L Unresectable or Metastatic HCC Announced November 11, 2026
Novocure enters clinical trial collaboration and supply agreement with Verastem Oncology to evaluate TTFields therapy, chemo and VS-7375 to treat pancreatic cancer November 4, 2026
Results from UNICORN Ph 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer Published in Nature Medicine November 4, 2026
Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study October 28, 2026
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Ph 2/3 Clinical Trial Collaboration to Evaluate Ivonescimab in 1L BTC October 27, 2026
VS-7375 Demonstrates 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) October 20, 2026
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer October 20, 2026
GOBLET Ph 1/2 study Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results expected in H1 2027 October 20, 2026
FDA granted Fast Track designation to QTX3034 + cetuximab for KRASG12D-mutant CRC, with or without FOLFOX chemotherapy October 20, 2026
Positive Ph 2 Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic CRC Announced October 20, 2026
RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer October 20, 2026
First Patient Dosed in Hong Kong Clinical Trial of PLT012 for Liver Cancer Expansion October 20, 2026
NDA resubmitted to FDA for Camrelizumab + Rivoceranib in 1L Unresectable or Metastatic HCC October 20, 2026
Jemperli (dostarlimab) approved in US for adults with MSI-H/dMMR locally advanced rectal cancer October 20, 2026